Top Page
Dr. Martens Plc
(LSE:DOCS)
Dr. Martens Plc (DOCS) vs. iShares MSCI United Kingdom ETF (EWC)
Dr. Martens Plc Business Overview & Revenue Model
Dr. Martens Plc Earnings Call Summary
Dr. Martens Plc Financial Statement Overview
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 787.60M | 877.10M | 1.00B | 908.30M | 773.00M |
| Gross Profit | 511.70M | 502.90M | 563.90M | 542.10M | 436.70M |
| EBITDA | 110.50M | 197.50M | 204.40M | 266.00M | 145.10M |
| Net Income | 4.50M | 69.20M | 128.90M | 181.20M | 34.70M |
Balance Sheet | |||||
| Total Assets | 889.80M | 952.40M | 992.60M | 859.10M | 651.80M |
| Cash, Cash Equivalents and Short-Term Investments | 155.90M | 111.10M | 157.50M | 228.00M | 113.60M |
| Total Debt | 404.10M | 468.60M | 445.80M | 393.80M | 366.40M |
| Total Liabilities | 523.40M | 584.20M | 588.40M | 530.90M | 502.10M |
| Stockholders Equity | 366.40M | 368.20M | 404.20M | 328.20M | 149.70M |
Cash Flow | |||||
| Free Cash Flow | 177.60M | 139.50M | 20.30M | 148.60M | 128.80M |
| Operating Cash Flow | 196.30M | 167.90M | 71.70M | 173.60M | 146.10M |
| Investing Cash Flow | -15.30M | -25.50M | -52.20M | -25.00M | -17.30M |
| Financing Cash Flow | -134.20M | -185.90M | -92.30M | -36.20M | -120.10M |
Dr. Martens Plc Technical Analysis
Dr. Martens Plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | £1.27B | 12.22 | 5.01% | ― | -10.46% | 396.13% | |
68 Neutral | £797.73M | 172.87 | 1.23% | 222.76% | -10.20% | -93.32% | |
66 Neutral | £7.14B | 24.04 | 10.25% | 101.58% | 5.96% | -33.04% | |
63 Neutral | $17.10B | 10.79 | -8.01% | 2.94% | 1.62% | -25.73% | |
61 Neutral | £435.02M | ― | -62.59% | ― | -15.86% | -18.46% | |
55 Neutral | £482.15M | ― | -27.20% | ― | -14.37% | -28.78% | |
48 Neutral | £261.33M | ― | -96.36% | ― | -16.32% | -202.39% |
Dr. Martens Plc Corporate Events
Dr. Martens Plc announced transactions involving its directors and persons discharging managerial responsibility under the company’s Share Incentive Plan (SIP). On July 11, 2025, CEO Ije Nwokorie and CFO Giles Wilson each acquired 194 Partnership Shares at 77.45 pence per share and were awarded an equal number of Matching Shares. This initiative reflects the company’s commitment to employee investment and aligns managerial interests with shareholder value, potentially strengthening stakeholder confidence.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £0.85 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens PLC announced the successful passing of all resolutions at its Annual General Meeting, including both Ordinary and Special Resolutions. The approval of these resolutions, such as the re-election of directors and the authorization for share allotment, reflects strong shareholder support and positions the company for continued strategic initiatives. This outcome is likely to reinforce Dr. Martens’ operational stability and strategic direction, potentially impacting its market positioning positively.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £0.90 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens plc announced that trading since the beginning of the financial year has met expectations, with no changes to FY26 guidance. The company reported strong performance in the Americas Direct to Consumer channel, particularly in retail, while the EMEA region faced challenges, especially in the UK. The APAC region showed good growth, notably in South Korea. The company is optimistic about its Autumn/Winter order books and is focusing on its new consumer-first Levers for Growth strategy to engage more consumers and expand into new markets.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £0.85 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens plc has announced that its total issued ordinary share capital consists of 966,315,401 shares, each with a voting right, and none held in Treasury. This information is crucial for shareholders to determine their notification requirements under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £0.85 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens plc announced the granting of Performance Share Awards to key directors under its Long Term Incentive Plan, aligning executive compensation with company performance over the next three years. This strategic move aims to enhance shareholder value and strengthen the company’s market position by focusing on targets such as cumulative earnings per share, total shareholder return, and operating cash flow conversion.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £0.85 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens plc has released its 2025 Annual Report and Notice of Annual General Meeting, which are available for inspection at the National Storage Mechanism and on the company’s website. This announcement is part of the company’s compliance with UK Listing Rules, and it includes details about the upcoming Annual General Meeting scheduled for July 10, 2025. The release of these documents is a routine part of Dr. Martens’ corporate governance, providing transparency and information to stakeholders about the company’s financial performance and strategic plans.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £0.85 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens plc announced that its directors and persons discharging managerial responsibilities (PDMRs) have participated in the company’s Share Incentive Plan (SIP), acquiring Partnership Shares and receiving Matching Shares. This initiative, approved by HMRC, allows employees to purchase shares from their monthly salary and receive additional shares at no cost, potentially enhancing employee engagement and aligning interests with shareholders.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £0.85 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens PLC has announced its preliminary results for the fiscal year ending March 2025, highlighting a strategic shift to a consumer-first approach to drive growth. Despite a challenging economic environment, the company achieved its FY25 objectives, including returning its Americas direct-to-consumer channel to growth and delivering significant cost savings. The strategic update, ‘Levers For Growth,’ aims to expand market reach by engaging more consumers and optimizing distribution. With a strong balance sheet and cash generation, Dr. Martens is poised for sustainable, profitable growth, targeting new markets and leveraging its iconic brand and high-quality products.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £60.00 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens Plc has announced that its total issued ordinary share capital consists of 965,229,918 shares, each with one voting right, and no shares are held in Treasury. This information is crucial for shareholders to determine their interest in the company under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £0.85 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens Plc announced that directors and persons discharging managerial responsibilities, including CEO Ije Nwokorie and CFO Giles Wilson, have participated in the company’s Share Incentive Plan (SIP). Under this scheme, they purchased Partnership Shares at 57.45 pence each and received an equal number of Matching Shares at no cost. This move aligns with the company’s strategy to engage employees through equity participation, potentially enhancing stakeholder alignment and motivation.
The most recent analyst rating on (GB:DOCS) stock is a Hold with a £0.85 price target. To see the full list of analyst forecasts on Dr. Martens Plc stock, see the GB:DOCS Stock Forecast page.
Dr. Martens Plc has announced its total voting rights, with an issued ordinary share capital consisting of 965,190,393 shares, each carrying one voting right. This disclosure is in line with FCA’s rules and helps shareholders determine their notification requirements regarding their interests in the company, impacting transparency and stakeholder engagement.